NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma

Tang, Yan; Hu, Chunsheng

doi:10.1155/2021/5031479

Cited by 6 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have reported NMU expression in various organs and tissues was a kind of poor prognosis of lung cancer markers. 11 According to the study, NMU also regulates the development of lung adenocarcinoma CAMP signal pathway and has close ties to lung adenocarcinoma cell proliferation. 12 UBE2C affects the cell cycle of renal cell carcinoma and migration and promotes carcinogenesis in cancer.…”

Section: Discussionmentioning

confidence: 99%

Diagnosis and Prognosis of Thyroid Cancer by Immune-related Genes

Li,

Zhao

2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Background: Thyroid carcinoma (THCA) is the most common malignant endocrine tumor with low mortality and a relatively good prognosis. Immune genes have attracted much attention as molecular markers of THCA prognosis and potential targets of immunotherapy. Methods: Our study analyzed the transcriptome and clinical data of immune-related genes (IRGs) of THCA in gene expression omnibus, the cancer genome atlas-THCA, and ImmPort databases. By univariate Cox regression analysis, 15 genes were significantly correlated with the survival of patients with THCA. Five IRGs (NMU, UBE2C, CDKN2A, COL19A1, and GPM6A) were selected by LASSO regression analysis as independent prognostic factors to construct a disease-free survival-related prognostic risk model. Results: Kaplan-Meier survival analysis showed that there was a significant difference in disease-free survival between high and low-risk groups. The higher the risk score, the worse the survival of patients. Clinical correlation analysis showed that age and Stage stage of patients were correlated with risk score (P < 0.05). Quantitative real-time polymerase chain reaction confirmed that there were differences in the expression of 5 IRGs between tumor tissues and normal thyroid tissues. Spearman correlation analysis indicated that the relative expression levels of NMU, CDKN2A, UBE2C, COL19A1, and GPM6A were positively correlated with programmed death-ligand 1 and recombinant a disintegrin and metalloproteinase with thrombospondin 1. Conclusion: Based on the bioinformatics method, we constructed a prognosis evaluation model and risk score system of IRGs in THCA, which provided a reference for predicting the prognosis of patients with THCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnosis and Prognosis of Thyroid Cancer by Immune-related Genes

Li,

Zhao

2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Therefore, NMU inhibits the growth of these tumor cells. However, in bladder cancer ( 46 ), endometrial carcinoma ( 47 , 48 ) and breast cancer ( 49 ), lung adenocarcinoma ( 50 ), NMU overexpression can promote tumor cell growth, enhance tumor formation and metastasis, and increase tumor drug resistance. The latest study found for the first time that NMUR2 activation promoted signaling in colorectal cancer (CRC) cells, and that NMU improves the mobility and invasiveness of NMUR2-positive CRC cells ( 51 ).…”

Section: Discussionmentioning

confidence: 99%

Insights Into the Research Status of Neuromedin U: A Bibliometric and Visual Analysis From 1987 to 2021

Liu

Wang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Neuromedin U (NMU) is a regulatory peptide that is widely distributed throughout the body and performs a variety of physiological functions through its corresponding receptors. In recent years, NMU has become the focus of attention in various fields of research as its diverse and essential functions have gradually been elucidated. However, there have been no bibliometrics studies on the development trend and knowledge structure of NMU research. Therefore, in this study, we used VOSviewer software to statistically analyze scientific data from articles related to NMU to track the developmental footprint of this research field, including relevant countries, institutions, authors, and keywords. We retrieved a total of 338 papers related to NMU, written by 1,661 authors from 438 organizations of 41 countries that were published in 332 journals. The first study on NMU was reported by a group in Japan in 1985. Subsequently, nine articles on NMU were published from 1987 to 2006. A small leap in this field could be detected in 2009, with 30 articles published worldwide. Among the various countries in which this research has been performed, Japan and the United States have made the most outstanding contributions. Miyazato M, Kangawa K, and Mori K from the Department of Biochemistry, National Retrain and Cardiovascular Center Research Institute in Japan were the most productive authors who have the highest number of citations. Keyword analysis showed six clusters: central-nervous-system, homeostasis, energy metabolism, cancer, immune inflammation, and food intake. The three most highly cited articles were associated with inflammation. Overall, this study demonstrates the research trends and future directions of NMU, providing an objective description of the contributions in this field along with reference value for future research.

show abstract

“…In the past decade, the treatment of LUAD patients has made great progress, including surgery, radiotherapy, chemotherapy, or targeted therapy [ 4 , 5 ]. However, the outcomes of patients with LUAD recurrence are still poor [ 6 ]. Recent research has confirmed the potential of the targeted therapy, which blocks the upgrowth of lung cancer cells by inhibiting the initiation of vital oncogenic molecules that drive the progression of LUAD [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…However, the outcomes of patients with LUAD recurrence are still poor [ 6 ]. Recent research has confirmed the potential of the targeted therapy, which blocks the upgrowth of lung cancer cells by inhibiting the initiation of vital oncogenic molecules that drive the progression of LUAD [ 6 ]. Although targeted therapy has achieved gratifying results in the early treatment of LUAD and shown promising potential, drug resistance's existence and continuous development often directly lead to treatment failure [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma

Wang

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. Lung adenocarcinoma (LUAD) is the most common form of lung cancer, accounting for 30% of all cases and 40% of all non-small-cell lung cancer cases. Immune-related genes play a significant role in predicting the overall survival and monitoring the status of the cancer immune microenvironment. The present study was aimed at finding an immune-related gene signature for predicting LUAD patient outcomes. Methods. First, we chose the TCGA-LUAD project in the TCGA database as the training cohort for model training. For model validating, we found the datasets of GSE72094 and GSE68465 in the GEO database and took them as the candidate cohorts. We obtained 1793 immune-related genes from the ImmPort database and put them into a univariate Cox proportional hazard model to initially look for the genes with potential prognostic ability using the data of the training cohort. These identified genes then entered into a random survival forests-variable hunting algorithm for the best combination of genes for prognosis. In addition, the LASSO Cox regression model tested whether the gene combination can be further shrinkage, thereby constructing a gene signature. The Kaplan-Meier, Cox model, and ROC curve were deployed to examine the gene signature’s prognosis in both cohorts. We conducted GSEA analysis to study further the mechanisms and pathways that involved the gene signature. Finally, we performed integrating analyses about the 22 TICs, fully interpreted the relationship between our signature and each TIC, and highlighted some TICs playing vital roles in the signature’s prognostic ability. Results. A nine-gene signature was produced from the data of the training cohort. The Kaplan-Meier estimator, Cox proportional hazard model, and ROC curve confirmed the independence and predictive ability of the signature, using the data from the validation cohort. The GSEA analysis results illustrated the gene signature’s mechanism and emphasized the importance of immune-related pathways for the gene signature. 22 TICs immune infiltration analysis revealed resting mast cells’ key roles in contributing to gene signature’s prognostic ability. Conclusions. This study discovered a novel immune-related nine-gene signature (BTK, CCR6, S100A10, SEMA3C, GPI, SCG2, TNFRSF11A, CCL20, and DKK1) that predicts LUAD prognosis precisely and associates with resting mast cells strongly.

show abstract

NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma

Cited by 6 publications

References 32 publications

Diagnosis and Prognosis of Thyroid Cancer by Immune-related Genes

Diagnosis and Prognosis of Thyroid Cancer by Immune-related Genes

Insights Into the Research Status of Neuromedin U: A Bibliometric and Visual Analysis From 1987 to 2021

A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma

Contact Info

Product

Resources

About